Boston Scientific S-ICD™ System Named Most Innovative Product at Cardiostim 2012
S-ICD® System selected as most innovative in the field of Electrophysiology and Cardiac Techniques

Attendees of Cardiostim 2012, a global medical conference held recently in Nice, France, have selected the S-ICD® System recently acquired by Boston Scientific Corporation (NYSE: BSX) as the most innovative product in the sector of Electrophysiology and Cardiac Techniques.

Cardiostim conducted a survey among the 5,600 conference attendees to select the industry's most innovative products or services.

"We are very proud of this recognition which shows the interest and appreciation of the S-ICD System in the EP community," said Pierre Chauvineau, vice president and general manager of Boston Scientific's international S-ICD team.

"The Innovation Award validates our view that the S-ICD System represents a truly revolutionary and ground-breaking new option for patients," said Michael Onuscheck, senior vice president and president of Boston Scientific EMEA.

Cameron Health, Inc. developed the world's first and only commercially available subcutaneous (below the skin) implantable cardioverter defibrillator - the S-ICD System - which is an important new therapy alternative for patients at risk of sudden cardiac arrest. Boston Scientific acquired the S-ICD System when it completed its acquisition of Cameron Health earlier this month.

Unlike conventional implantable cardioverter defibrillators (ICDs), which require thin, insulated wires (leads) to pass through the venous system and into the heart, the entire S-ICD System sits just below the skin and leaves the heart and blood vessels untouched.

The S-ICD System received CE Mark in 2009 and is commercially available in many countries in Europe, as well as New Zealand. In the United States, the S-ICD System is currently under review for approval by the Food and Drug Administration. It is limited under U.S. law to investigational use only, and is not available for sale in the U.S.

About Boston Scientific 
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit and connect onTwitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding product launches and launch cadence, clinical trials and impact of data, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A ? Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A ? Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

1Survival probability is comprised of all RELIANCE and RELIANCE G models combined as one population. Data source and data cut off is based on the BSC Q2 2012 Product Performance report. Data and calculations on file.
DISCLAIMER: Please be informed that in some EU countries (Bulgaria, Cyprus, Estonia, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Belgium , Netherlands, Slovenia and Spain) medical device advertisement to general public is not permitted. Therefore, if you are accessing this website from one of those countries and you are not a healthcare professional, you need to exit this site immediately, since you would be viewing information that may not be legally allowed under the laws of your country of residence. Should you disregard this warning notice, Boston Scientific declines any liability as to your access to your access to such information.